Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus Target Price from Analysts

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) have been given an average rating of “Buy” by the five ratings firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.33.

CRBU has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a report on Wednesday, March 19th. Bank of America lowered their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th.

Institutional Investors Weigh In On Caribou Biosciences

Several institutional investors have recently bought and sold shares of CRBU. Geode Capital Management LLC raised its holdings in shares of Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares during the last quarter. Barclays PLC lifted its position in Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after buying an additional 71,463 shares in the last quarter. US Bancorp DE boosted its stake in shares of Caribou Biosciences by 3,524.2% during the 4th quarter. US Bancorp DE now owns 27,218 shares of the company’s stock worth $43,000 after buying an additional 26,467 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Caribou Biosciences by 19.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock valued at $1,449,000 after acquiring an additional 118,325 shares in the last quarter. Finally, FMR LLC increased its position in shares of Caribou Biosciences by 7.4% in the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after acquiring an additional 109,606 shares during the last quarter. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $0.94 on Friday. The firm has a market capitalization of $87.34 million, a price-to-earnings ratio of -0.57 and a beta of 2.34. The company’s 50 day simple moving average is $1.23 and its 200 day simple moving average is $1.71. Caribou Biosciences has a fifty-two week low of $0.88 and a fifty-two week high of $5.15.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.08 million for the quarter, compared to analysts’ expectations of $2.11 million. As a group, analysts predict that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.